Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization

作者: Bat-Chen R Avraham-Lubin , Murat Hasanreisoglu , Olga Dratviman-Storobinsky , Nitza Goldenberg-Cohen

DOI:

关键词:

摘要: Purpose: This study sought to characterize the expression of angiogenesis-related genes in a mouse model corneal neovascularization, either untreated or after treatment with single injection bevacizumab by three different routes. In addition, effectiveness was compared rabbit model. Methods: A chemical burn induced mid-cornea right eye 119 mice; 56 them were and 63 bevacizumab-treated. Neovascularization evaluated 2, 4, 8, 10, 14 days later using digital photos, angiography India ink perfusion. The relative area new blood vessels analyzed slit-lamp examination vivo on histological flat-mount sections. levels gene involved angiogenic process vascular endothelial growth factor [VEGF], insulin-like factor-1 [IGF-1], pigment epithelium derived [PEDF], macrophage-inflammatory protein-2 [MIP-2]) measured real-time polymerase chain reaction. Six rabbits underwent same injury treatment, response Results: first observed two injury. affected section increased from 11.24% (±7.0) 47.42% (±25.4) day 8 50.62% (±24.7) 10. mice treated bevacizumab, neovascularization significantly lower at peak time points (p<0.005): 24.90% (±21.8) 28.29% (±20.9) Spontaneous regression both groups, 26.98% (±19.9) 10.97% (±10.8) bevacizumab-treated (p<0.005). Rabbits also showed 8-10, significant following intracameral injection. mice, intraocular (intravitreal, intracameral) more effective than subconjuctival VEGF upregulated but slightly less mice. PEDF decreased group, peaked (above baseline) days, it had already 8. IGF-1 early model; there only slight change group increase group. MIP-2 groups stage returned baseline 14. Conclusions: Bevacizumab partially inhibits progressive damage Treatment is when administered via subconjunctival route. clinical findings are compatible angiographic histologic data supported molecular analysis showing partial proangiogenic genes. mechanisms inflammation warrant further exploration. These may have important therapeutic implications setting.

参考文章(78)
Napoleone Ferrara, None, The role of VEGF in the regulation of physiological and pathological angiogenesis Mechanisms of Angiogenesis. pp. 209- 231 ,(2005) , 10.1007/3-7643-7311-3_15
Patricia Lee, Cindy C. Wang, Anthony P. Adamis, Ocular neovascularization: an epidemiologic review. Survey of Ophthalmology. ,vol. 43, pp. 245- 269 ,(1998) , 10.1016/S0039-6257(98)00035-6
Banumathi Elayappan, Haribalaganesh Ravinarayannan, Sheik Pran Babu Sardar Pasha, Kyung-jin Lee, Sangiliyandi Gurunathan, PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis. ,vol. 12, pp. 313- 324 ,(2009) , 10.1007/S10456-009-9153-5
Lilly Speicher, Wolfgang Philipp, Christian Humpel, Expression of Vascular Endothelial Growth Factor and Its Receptors in Inflamed and Vascularized Human Corneas Investigative Ophthalmology & Visual Science. ,vol. 41, pp. 2514- 2522 ,(2000)
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
In-Cheon You, In-Seong Kang, Seung-Hyun Lee, Kyung-Chul Yoon, Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization Acta Ophthalmologica. ,vol. 87, pp. 653- 658 ,(2009) , 10.1111/J.1755-3768.2008.01399.X
Luiz F.M. Barros, Rubens Belfort-Jr, The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea Anais Da Academia Brasileira De Ciencias. ,vol. 79, pp. 389- 394 ,(2007) , 10.1590/S0001-37652007000300004
Steven J. Harper, David O. Bates, VEGF-A splicing: the key to anti-angiogenic therapeutics? Nature Reviews Cancer. ,vol. 8, pp. 880- 887 ,(2008) , 10.1038/NRC2505
Felix Bock, Jasmine Onderka, Carmen Rummelt, Tina Dietrich, Bjo¨rn Bachmann, Friedrich E. Kruse, Ursula Schlo¨tzer-Schrehardt, Claus Cursiefen, Safety profile of topical VEGF neutralization at the cornea. Investigative Ophthalmology & Visual Science. ,vol. 50, pp. 2095- 2102 ,(2009) , 10.1167/IOVS.07-1129